# ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

> **NCT07327034** · PHASE2 · RECRUITING · sponsor: **Abbisko Therapeutics Co, Ltd** · enrollment: 141 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** ABSK-011+BSC
- **DRUG:** Placebo+BSC

## Key facts

- **NCT ID:** NCT07327034
- **Lead sponsor:** Abbisko Therapeutics Co, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-13
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 141 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07327034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07327034, "ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07327034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*